Spots Global Cancer Trial Database for Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer

Official Title: A Pilot Study to Test a Cognitive-Behavioral Model for Dyspnea in Patients With Lung Cancer

Study ID: NCT05304793

Conditions

Lung Non-Small Cell Carcinoma

Lung Small Cell Carcinoma

Interventions

Best Practice

Cognitive Behavior Therapy

Questionnaire Administration

Study Description

Brief Summary: This trial studies the effect of a form of cognitive-behavioral therapy, Take a Breath, on reducing the intensity and frequency of dyspnea (difficulty breathing) in patients with lung cancer. Take a Breath consists of individual therapy sessions that educate patients on dyspnea and provides coping strategies.

Detailed Description: PRIMARY OBJECTIVE: I. To determine the acceptability (based on patient satisfaction), tolerability (based on rate of symptom exacerbation from pre- to post-treatment), and feasibility (based on number of patients agreeing to be participate, adherence rate, and retention rate of treatment) of Take a Breath (TAB), a skills-based cognitive-behavioral treatment lasting 4 weekly hour-long sessions targeting dyspnea and related distress and impairment, in adults with lung cancer (N=40). SECONDARY OBJECTIVES: I. To provide preliminary data on the effectiveness of TAB on dyspnea and related distress and impairment. II. To test cognitive-behavioral variables (physical symptoms, thoughts, behaviors, and emotions) as predictors of dyspnea severity and anxiety sensitivity as a moderator. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients participate in 4 weekly TAB in-person or video conference sessions over 1 hour each that provide them with skills to cope with their dyspnea. Patients also receive treatment handouts, a compact disk (CD) with an audio file with instructions for progressive muscle relaxation, and a pulse oximeter. Patients may receive additional support calls over 10-15 minutes from the TAB provider within 1 week following each session. ARM II: Patients receive usual management of dyspnea from the treating physician. After completion of study, patients are followed up at 1 month.